MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

Personalised, knowledge-rich relationships the key to partner success How Crayon is reshaping distributor-partner relationships through trust and expertise By Crayon 28 Oct 2025 5 mins IT Management ...